Moreover, this study demonstrated that not only CML but also other MR-induced modifications result in binding to AGE receptors, because glycated BLG with low levels of CML also induced binding to these receptors. The gene discussed is NR3C2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.